SELLAS Life Sciences Group, Inc. - חוב לטווח קצר של החברה SLS

SELLAS Life Sciences minimizes biopharmaceutical risks by developing immunotherapy to prevent tumor recurrence. The business focuses on combating aggressive leukemia, occupying a specific oncology segment. The current metric is 0.00. Stability is provided by vaccine development in the final stages of R&D and patent protection against generics. This price chart below clearly demonstrates the financial parameters of this asset.

For SELLAS Life Sciences (SLS), which is developing a leukemia vaccine, short-term borrowings under one year reflect current liquidity. This metric aggregates all obligations with a maturity of less than twelve months. The trend of this indicator measures the company's ability to fund clinical phases without emergency capital raises. An upward curve signals an increasing debt load, while a decline indicates the optimization of liabilities. This is a key solvency indicator prior to the company's commercial market entry.